BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19811811)

  • 21. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
    Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
    Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
    Pan E; Yu D; Yue B; Potthast L; Chowdhary S; Smith P; Chamberlain M
    J Neurooncol; 2012 Oct; 110(1):111-8. PubMed ID: 22832897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
    Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
    Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
    Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
    Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
    Look KY; Sandler A; Blessing JA; Lucci JA; Rose PG;
    Gynecol Oncol; 2004 Feb; 92(2):644-7. PubMed ID: 14766260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
    Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
    Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
    Campos SM; Penson RT; Matulonis U; Horowitz NS; Whalen C; Pereira L; Tyburski K; Roche M; Szymonifka J; Berlin S
    Gynecol Oncol; 2013 Feb; 128(2):215-20. PubMed ID: 22885865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
    Sonpavde G; Periman PO; Bernold D; Weckstein D; Fleming MT; Galsky MD; Berry WR; Zhan F; Boehm KA; Asmar L; Hutson TE
    Ann Oncol; 2010 Feb; 21(2):319-324. PubMed ID: 19633050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.
    Komatsu Y; Ohki E; Ueno N; Yoshida A; Toyoshima Y; Ueda E; Houzawa H; Togo K; Nishida T
    Jpn J Clin Oncol; 2015 Nov; 45(11):1016-22. PubMed ID: 26373318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers.
    Wu C; Mikhail S; Wei L; Timmers C; Tahiri S; Neal A; Walker J; El-Dika S; Blazer M; Rock J; Clark DJ; Yang X; Chen JL; Liu J; Knopp MV; Bekaii-Saab T
    Br J Cancer; 2015 Jul; 113(2):220-5. PubMed ID: 26151457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
    N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.